Search Results - "FRANKEL, Arthur E"
-
1
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
Published in Neoplasia (New York, N.Y.) (01-10-2017)“…This is the first prospective study of the effects of human gut microbiota and metabolites on immune checkpoint inhibitor (ICT) response in metastatic melanoma…”
Get full text
Journal Article -
2
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Published in Blood (17-07-2014)“…This is the first prospective study of treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy…”
Get full text
Journal Article -
3
Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases
Published in Journal of immunotherapy (1997) (01-10-2019)“…By targeting receptors that serve to downregulate the cellular immune system, monoclonal antibodies such as ipilimumab and nivolumab have transformed the…”
Get full text
Journal Article -
4
Roles of the cGAS-STING Pathway in Cancer Immunosurveillance and Immunotherapy
Published in Annual review of cancer biology (04-03-2019)“…Cyclic GMP-AMP synthase (cGAS) is a cytosolic DNA sensor that initiates innate immune responses. DNA-bound cGAS produces cyclic GMP-AMP (cGAMP), which…”
Get full text
Journal Article -
5
Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies
Published in Biomedicines (05-01-2019)“…Overcoming the leukemia stem cell resistance to intensive chemotherapy has been an area of extensive research over the last two decades. Advances and greater…”
Get full text
Journal Article -
6
Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells
Published in Journal of neuro-oncology (01-03-2015)“…In this study, we attempt to target Arginine auxotrophy in glioblastoma multiforme (GBM) cells using a pegylated recombinant human Arginase I cobalt [HuArgI…”
Get full text
Journal Article -
7
Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients
Published in Neoplasia (New York, N.Y.) (01-04-2017)“…Abstract This is the first prospective study of a combination therapy involving a cardenolide and a MEK inhibitor for metastatic melanoma. Whereas BRAF mutant…”
Get full text
Journal Article -
8
Developing EZH2-Targeted Therapy for Lung Cancer
Published in Cancer discovery (01-09-2016)“…Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown…”
Get more information
Journal Article -
9
The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors
Published in Acta haematologica (01-03-2020)“…The gut microbiota plays a significant role in health and disease, including cancer development and treatment. The importance of the gut microbiota in the…”
Get more information
Journal Article -
10
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
Published in Integrative Cancer Therapies (01-01-2019)“…The past decade has seen tremendous advances in both our understanding of cancer immunosuppressive microenvironments and colonic bacteria facilitated by immune…”
Get full text
Book Review Journal Article -
11
Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
Published in Haematologica (Roma) (01-06-2015)“…Resimmune is a second-generation recombinant immunotoxin composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain…”
Get full text
Journal Article -
12
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies
Published in Clinical cancer research (15-03-2015)“…The novel bispecific ligand-directed toxin (BLT) DT2219 consists of a recombinant fusion between the catalytic and translocation enhancing domain of diphtheria…”
Get full text
Journal Article -
13
Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia
Published in Protein and peptide letters (01-04-2013)“…Red blood cell (RBC) encapsulated L-asparaginase is a novel therapeutic for the treatment of asparagine auxotrophic malignancies. The enzyme-loaded red blood…”
Get more information
Journal Article -
14
Tumor endothelial marker 8 promotes cancer progression and metastasis
Published in Oncotarget (10-07-2018)“…Every year more than 8 million people suffer from cancer-related deaths worldwide [1]. Metastasis, the spread of cancer to distant sites, accounts for 90% of…”
Get full text
Journal Article -
15
Regulation of HMGB1 release by autophagy
Published in Autophagy (16-02-2009)“…The characteristics of tumor cell killing by an anti-cancer agent can determine the long-term effectiveness of the treatment. For example, if dying tumor…”
Get full text
Journal Article -
16
RLIP76 and Cancer
Published in Clinical cancer research (15-07-2008)“…RLIP76 is a multifunctional membrane protein that transports glutathione conjugates of electrophilic compounds and other xenobiotics including chemotherapy…”
Get full text
Journal Article -
17
Response to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus
Published in Clinical case reports (01-06-2021)“…A 61‐year‐old male on everolimus had chronic SARS‐CoV‐2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with…”
Get full text
Journal Article -
18
Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
Published in Clinical case reports (01-04-2021)“…An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated…”
Get full text
Journal Article -
19
A STING-activating nanovaccine for cancer immunotherapy
Published in Nature nanotechnology (01-07-2017)“…STING-activating nanoparticle vaccines achieve robust activation of tumour-specific T cells for cancer immunotherapy. The generation of tumour-specific T cells…”
Get full text
Journal Article -
20
Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma
Published in Nature communications (29-09-2016)“…Nature Communications 7 Article number:12336 (2016); Published 22 August 2016; Updated 29 September 2016 Arthur E. Frankel, who helped to interpret the…”
Get full text
Journal Article